Showing results (1-10 of 200) with videos related to
Sort By:
Pageof 20
PPAR Research|January 30, 2007
Resolving the Two "Bony" Faces of PPAR-gammaBeata Lecka-Czernik, Larry J SuvaBone|September 3, 2005
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fatOxana P Lazarenko, Sylwia O Rzonca, Larry J Suva, et al.Idrugs : the Investigational Drugs Journal|November 4, 2010
Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitusBeata Lecka-CzernikBone|July 16, 2011
Marrow fat metabolism is linked to the systemic energy metabolismBeata Lecka-CzernikCurrent Osteoporosis Reports|September 3, 2010
Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosisBeata Lecka-CzernikCurrent Opinion in Investigational Drugs (London, England : 2000)|September 25, 2009
Bone as a target of type 2 diabetes treatmentBeata Lecka-CzernikClinical Reviews in Bone and Mineral Metabolism|April 2, 2013
Safety of Anti-Diabetic Therapies on BoneBeata Lecka-CzernikDiabetologia|April 24, 2017
Diabetes, bone and glucose-lowering agents: basic biologyBeata Lecka-CzernikCurrent Osteoporosis Reports|April 29, 2010
PPARs in bone: the role in bone cell differentiation and regulation of energy metabolismBeata Lecka-CzernikEndocrinology|March 3, 2007
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged boneOxana P Lazarenko, Sylwia O Rzonca, William R Hogue, et al.Pageof 20